Concurrent Technologies – next Monday’s Finals to show good growth and record order intake, shares 192p brokers TP 270p
- Mark Watson-Mitchell
- 23 hours ago
- 4 min read
Mark Watson-Mitchell - 09.04.2026
Next Monday, 13th April, Concurrent Technologies (LON:CNC) will release its Final Results to end-December 2025, they will be good and show real progress going forward.
The £167m-capitalised group is a designer and manufacturer of leading-edge computer products, systems, and mission-critical solutions used in high-performance markets by some of the world's major OEMs,
At the end of February, the group’s shares were trading at a 278p High, then the recent conflict hit the markets and this company too, easing them back to 173.50p before showing some recovery to 192p
The Business
Founded in 1985 to develop Multibus II boards, this group has expanded its offering over four decades to become a trusted, reliable solutions provider in critical embedded applications.
From medical advancements to cutting-edge aerospace, the Colchester-based company delivers high-performance embedded computer solutions that are the backbone of critical systems across various industries.
It has a proven record of delivering technology to the world’s leading OEMs in defence, including companies such as Boeing, Raytheon, MBDA, BAE Systems etc.
From its design centre and manufacturing hub in the UK to its systems design facility, and sales and support hub in the US, its employees are working together to make sure its products are reliable and built to last.
The group has four main facilities: Colchester in the UK is the manufacturing centre of excellence; Theale in the UK is the primary design centre; Woburn MA is the US HQ with sales and customer support capability and while Los Angeles, CA is the systems design and manufacturing centre.
Concurrent develops and manufactures high-end embedded plug-in cards and systems for use in a wide range of high-performance, long-life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments.
The processor products feature Intel® processors, including the latest generation embedded Intel® Core™ processors, Intel® Xeon® and Intel Atom™ processors.
Latest Trading Update
On Tuesday 20th January, the group issued a Trading Update stating that it anticipates revenue and pre-tax profit for its 2025 year to be in line with market expectations, showing strong double-digit growth over FY24, with record order intake reaching approximately £47m compared to £41m in FY24.
The company declared that it ended 2025 with £14.4m in cash, up from £13.7m in FY24, and that a significant design services contract had been expanded to $6.2m, which is its largest single order to date.
Despite delays in US Department of Defence budget approvals, the company stated that it had good momentum entering the new financial year, supported by robust demand and a growing pipeline.
Management Comment
CEO Miles Adcock stated that:
"FY25 was another strong year for Concurrent, in which we continued to execute on our stated strategy, as planned.
With our new Los Angeles facilities now fully operational and the Colchester relocation expected to complete in H1 FY26, we believe the business is entering a new phase of operational capacity.
We will see prior design wins begin translating into meaningful orders, while strengthening and diversifying our portfolio of products and services to support long-term growth.
I am extremely proud of what our team has achieved and am excited by the scale of opportunity ahead."
The Equity
There are some 86.99m shares in issue.
The larger holders include Charley Stanley (11.335), Premier Miton Investors (8.40%), Hargreaves Lansdown Asset Management (7.75%), Interactive Investor (6.83%), Canaccord Genuity Wealth Management (5.01%), EFG Harris Allday (4.64%), Rathbone Investment Management (3.93%), AJ Bell Securities (3.03%), and Seguro Nominees (3.01%).
Analyst Views
At Singer Capital Markets, its trio of analysts (James Musker, Harold Evans and Roddy Davidson) rate the group’s shares as a Buy, with a Target Price of 270p.
For the 2025 year, their estimates are for revenues of £46.0m (£40.3m), with adjusted pre-tax profits of £6.2m (£5.2m), increasing earnings to 6.6p (5.2p) and lifting its dividend to 1.20p (1.10p) per share.
For the current year, they look for £52.0m sales, £8.0m profits, earnings of 8.0p and paying a dividend of 1.30p per share.
The year to end-December 2027, the analysts consider could show £60.0m in turnover, with £10.0m in profits, earnings of 9.9p and a 1.40p dividend.
Ian McInally, at Cavendish Capital Markets, also rates the shares as a Buy, but with a 256p Target Price, with very similar sales, profits, earnings and dividend estimates.
He notes that Concurrent describes entering the current financial year with good momentum, benefiting from the record order intake and an expanding pipeline of design wins, underpinning future revenue growth expectations.
My View
Do not be put off by this group’s high price-to-earnings ratio, currently some 39 times previous 2024 earnings, which drops to 27.5 times the estimated 2025 figure.
Looking forward puts the shares on just 24 times current, then 19 times prospective year earnings.
I await next week’s accompanying statement with its Final Results, in the meantime its shares at 192p offering growth, have strong appeal.
(Profile 09.04.26 @ 192p set a Target Price of 235p)
Comments